Selected Publications
Pratz KW, Koh B, Patel AG, Flatten KS, Poh W, Herman J, Dilley R, Harrell MI, Smith BD, Karp JE, Swisher EM, McDermitt MA, Kaufmann SH. Poly(ADP-ribose) polymerase inhibitor hypersensitivity in aggressive myeloproliferative neoplasms. Clin Cancer Res 22:3894-3902, 2016.
Patel AG*, Flatten KS*, Peterson KL, Beito TG, Schneider PS, Perkins AL, Harki DA, Kaufmann SH. Immunodetection of human topoisomerase I-DNA covalent complexes. Nucleic Acids Res 44:2816-2826, 2016. *Co-first authors
Patel AG*, De Lorenzo S*, Flatten KS*, Poirier GG, Kaufmann SH. Failure of iniparib to inhibit poly(ADP-ribose) polymerase in vitro. Clin Cancer Res 18(6):1655-1662, 2012. *Co-first authors
Patel AG, Flatten KS, Schneider PA, Dai NT, McDonald JS, Poirier GG, Kaufmann SH. Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes. J Biol Chem 287(6):4198-4210, 2012.
Huehls AM, Wagner JM, Huntoon CJ, Geng L, Erlichman C, Patel AG, Kaufmann SH, Karnitz LM. Poly(ADP-ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells. Cancer Res 71(14):4944-4954, 2011.
Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci USA 108(8):3406-3411, 2011.
Last update: August 2020